4^th Antibodies, Antibiotics and Bio Therapeutics Congress: R&D, Market and B2B

Dr. Bernhard Dietzschold was appointed Professor Emeritus in the Department of Microbiology & Immunology effective July 02, 2013, after service as Professor in the Department for 22 years. Dr. Dietzschold is a world leader in rabies virology. He has made a variety of seminal discoveries in the areas of rabies virus pathogenesis and immunity. Several of these stand out in providing the foundation for the development of new rabies vaccines and therapeutics. Dr. Dietzschold research has lead to over 150 peer-reviewed publications and numerous other professional and scientific contributions. Dr. Dietzschold is the Director of the WHO reference Center for Neurovirology of the Jefferson Center for Neurovirology, a position in which he will continue. He is also a member of the WHO expert Committee on Rabies.

Major Research interests are the pathogenesis of rabies, the immune mechanisms involved in virus clearance from the central nervous system (CNS), and the development of novel vaccines and immune therapeutics for pre- and post-exposure prophylaxis of rabies and other virus infections of the CNS.

Jagat Kanwar is an Associate Professor of Immunology & Cell Biology, and Group Leader in “Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research” at Deakin University, Australia. He did his PhD in 1993 from PGIMER, Chandigarh, India and worked as a Senior Scientist in The Auckland University, New Zealand for more than 10 years. He has a national and international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. His research is also focused on miRNA, aptamer, locked nucleic acid (LNA) LNA-modified chimeric aptamers-siRNA conjugates, and immunoliposomes technology and disease targeted drug discovery. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. He designed nanocarriers for applications in vaccines, immunotherapy, and drug delivery of antigens immunostimulatory ligands to dendritic cells and subsequent stimuli to T- lymphocytes, B-lymphocytes and TH17 cells

Cancer and chronic inflammatory diseases targeted nanomedicine based drug delivery siRNA, miRNA anti-sense targeted gene nanomedicine based technology to target cancer and inflammation Drug discovery with anticancer targets for cancer cell survival, death, arrest, and repair Development of recombinant proteins and searching new immunomodulatory and anti-inflammatory bioactives, proteins and peptides for cancer and neuroprotection Development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of colon and breast cancers Development of oral and intravenous administration of nanocarriers to overcome the challenging concept of drug resistance in various cancers Development of new generation safe, biodegradable, less toxic, disease targeted natural contrast materials for imaging Novel nano-medicinal based vaccines and immunotherapy Micro-fluidics and Lab-on-a-Chip devices for delivery and diagnosis

Fekadu Abebe has done his PhD in immunology, Faculty of Medicine, University of Oslo. He taught and supervised PhD and masterstudents in International Community Health. The positions held by him are Lecturer and researcher, Addis Abeba University, Head, Schistosomiasis Unit, PhD fellow, University of Oslo, Postodctoral fellow, University of Oslo, Scientist, University of Oslo till present.

Infectious diseases epidemiology and control Infection and immunity, including vaccines and vaccinations, and immunodiagnosis

William Whitford is Strategic Solutions Leader for BioProcess at GE Healthcare Life Sciences in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company as an R&D Team Leader developing products supporting biomass expansion, protein expression and virus secretion in mammalian and invertebrate cell lines. An invited lecturer at international conferences, William has published over 300 articles, book chapters and patents in a number of fields in the biotechnology arena.

Emerging Bioproduction Platforms and Technologies

Stephen D Silberstein is a Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University. He is a Fellow of the American College of Physicians, the American Academy of Neurology, and the American Headache Society. He has served the American Headache Society as President, Treasurer and Board of Directors member. He has served on the publications, Scientific, and Education Committees of the American Headache Society and was Co-Chairman of the Annual Scientific Meeting. Dr Silberstein is an active member of the American Academy of Neurology and was Co-Director of the national and international Headache Guideline Project, in cooperation with the Agency for Health Care Policy and Research. He was the Chairman of the International Headache Society meeting in Philadelphia in 2009. He is chairman of the headache research group of the World Federation of Neurology.

Stephen D Silberstein is a Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University. He is a Fellow of the American College of Physicians, the American Academy of Neurology, and the American Headache Society. He has served the American Headache Society as President, Treasurer and Board of Directors member. He has served on the publications, Scientific, and Education Committees of the American Headache Society and was Co-Chairman of the Annual Scientific Meeting. Dr Silberstein is an active member of the American Academy of Neurology and was Co-Director of the national and international Headache Guideline Project, in cooperation with the Agency for Health Care Policy and Research. He was the Chairman of the International Headache Society meeting in Philadelphia in 2009. He is chairman of the headache research group of the World Federation of Neurology.

William Whitford is Strategic Solutions Leader for BioProcess at GE Healthcare Life Sciences in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company as an R&D Team Leader developing products supporting biomass expansion, protein expression and virus secretion in mammalian and invertebrate cell lines. An invited lecturer at international conferences, William has published over 300 articles, book chapters and patents in a number of fields in the biotechnology arena.

Emerging Bioproduction Platforms and Technologies

Thea Sesardic has over 35 years’ experience in biomedical research with 25 years’ experience at NIBSC on regulatory research focusing on the 3Rs - replacement, reduction and refinement of animals in the field of biological products derived from bacterial toxins. Over 10 methods have been developed and implemented as part of the batch release function of the group for toxins, antitoxins and toxoid vaccines at NIBSC, reducing the use of animals by 1,000 a year at NIBSC alone. Several of the methods have also gone through international validation and are now regulatory standards. In her capacity as UK delegate on the European Pharmacopoeia group of experts, she has introduced new monographs and method chapters (eg. potency of human tetanus IgG, safety and potency of DT vaccines, replacing toxin challenge methods and replacing LD50 assays for Botulinum toxin for therapy) that continue to impact animal use in Europe and globally. She has contributed to several major revisions and manuals of methods to assess quality, safety and efficacy of DT vaccines as part of a WHO working group.

Bacteriology